Literature DB >> 10482581

Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.

M Lusky1, L Grave, A Dieterlé, D Dreyer, M Christ, C Ziller, P Furstenberger, J Kintz, D A Hadji, A Pavirani, M Mehtali.   

Abstract

In a previous study we showed that multiple deletions of the adenoviral regulatory E1/E3/E4 or E1/E3/E2A genes did not influence the in vivo persistence of the viral genome or affect the antiviral host immune response (Lusky et al., J. Virol. 72:2022-2032, 1998). In this study, the influence of the adenoviral E4 region on the strength and persistence of transgene expression was evaluated by using as a model system the human cystic fibrosis transmembrane conductance regulator (CFTR) cDNA transcribed from the cytomegalovirus (CMV) promoter. We show that the viral E4 region is indispensable for persistent expression from the CMV promoter in vitro and in vivo, with, however, a tissue-specific modulation of E4 function(s). In the liver, E4 open reading frame 3 (ORF3) was necessary and sufficient to establish and maintain CFTR expression. In addition, the E4 ORF3-dependent activation of transgene expression was enhanced in the presence of either E4 ORF4 or E4 ORF6 and ORF6/7. In the lung, establishment of transgene expression was independent of the E4 gene products but maintenance of stable transgene expression required E4 ORF3 together with either E4 ORF4 or E4 ORF6 and ORF6/7. Nuclear run-on experiments showed that initiation of transcription from the CMV promoter was severely reduced in the absence of E4 functions but could be partially restored in the presence of either ORF3 and ORF4 or ORFs 1 through 4. These results imply a direct involvement of some of the E4-encoded proteins in the transcriptional regulation of heterologous transgenes. We also report that C57BL/6 mice are immunologically weakly responsive to the human CFTR protein. This observation implies that such mice may constitute attractive hosts for the in vivo evaluation of vectors for cystic fibrosis gene therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482581      PMCID: PMC112848          DOI: 10.1128/JVI.73.10.8308-8319.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Adenovirus E4orf4 protein reduces phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of AP-1.

Authors:  U Müller; T Kleinberger; T Shenk
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

Review 2.  Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium.

Authors:  N E Bowles; Q Wang; J A Towbin
Journal:  Cardiovasc Res       Date:  1997-09       Impact factor: 10.787

Review 3.  Development of adenovirus vectors for the expression of heterologous genes.

Authors:  K L Berkner
Journal:  Biotechniques       Date:  1988 Jul-Aug       Impact factor: 1.993

4.  Adenovirus early region 4 and viral DNA synthesis.

Authors:  E Bridge; S Medghalchi; S Ubol; M Leesong; G Ketner
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

5.  Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mRNAs.

Authors:  K Nordqvist; K Ohman; G Akusjärvi
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

6.  Assessment of recombinant adenoviral vectors for hepatic gene therapy.

Authors:  Q Li; M A Kay; M Finegold; L D Stratford-Perricaudet; S L Woo
Journal:  Hum Gene Ther       Date:  1993-08       Impact factor: 5.695

7.  Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.

Authors:  H Gahéry-Ségard; V Molinier-Frenkel; C Le Boulaire; P Saulnier; P Opolon; R Lengagne; E Gautier; A Le Cesne; L Zitvogel; A Venet; C Schatz; M Courtney; T Le Chevalier; T Tursz; J G Guillet; F Farace
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

8.  Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription.

Authors:  T Kleinberger; T Shenk
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  Two adenovirus proteins with redundant activities in virus growth facilitates tripartite leader mRNA accumulation.

Authors:  K Ohman; K Nordqvist; G Akusjärvi
Journal:  Virology       Date:  1993-05       Impact factor: 3.616

10.  Analysis of synthesis, stability, phosphorylation, and interacting polypeptides of the 34-kilodalton product of open reading frame 6 of the early region 4 protein of human adenovirus type 5.

Authors:  D Boivin; M R Morrison; R C Marcellus; E Querido; P E Branton
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more
  7 in total

1.  Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization.

Authors:  M Rosa-Calatrava; L Grave; F Puvion-Dutilleul; B Chatton; C Kedinger
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D.

Authors:  Zsolt Ruzsics; Markus Wagner; Andrea Osterlehner; Jonathan Cook; Ulrich Koszinowski; Hans-Gerhard Burgert
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.

Authors:  V Molinier-Frenkel; H Gahery-Segard; M Mehtali; C Le Boulaire; S Ribault; P Boulanger; T Tursz; J G Guillet; F Farace
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection.

Authors:  R J O'Connor; P Hearing
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.

Authors:  Daniele Catalucci; Elisabetta Sporeno; Agostino Cirillo; Gennaro Ciliberto; Alfredo Nicosia; Stefano Colloca
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Viral and cellular factors that target the promyelocytic leukemia oncogenic domains strongly activate a glucocorticoid-responsive promoter.

Authors:  S Wienzek; M Dobbelstein
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.

Authors:  Michael A Thomas; Rui Song; Thorsten Demberg; Diego A Vargas-Inchaustegui; David Venzon; Marjorie Robert-Guroff
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.